Will this deal lead to Mankind Pharma focusing on exports too?
We have been very clear from the beginning that we don't want to get into exports with generic or me-too products. We always wanted products with a high level of entry barriers and complexity.
With the BSV deal, we now have branded products in some cases, there is no competition, and in others, there is limited competition (one or two players). For example, consider the AntiD product that BSV hasnearly 5-7 per cent of Indian mothers are Rh negative (blood group), which amounts to 8-10 million mothers.
Lack of preventive measures can cause brain damage or jaundice in & newborns. The mother needs to take a dose in the third trimester and within 72 hours after delivery with an Rh-positive child. Only 3040 per cent of expecting mothers adhere to this due to lack of awareness. BSV has the world's first and only recombinant for AntiRhoD, which has a valid patent until 2028. It also has vertically integrated in-house cell lines. If anyone tries to make any product of BSV, it would take five to 10 years at least. But we also feel there is huge potential for these products in the Indian market itself. Even after acquiring BSV, 87 per cent of the revenues of the entity will come from India. Wherever we have strong opportunities in the rest of the world, we will pursue them. Our ambition is to become a great company in India.
How do you wish to grow the synergies between BSV and Mankind?
Probably the fastest-growing therapy segment is infertility treatment. People are marrying late, then deciding to have a baby later on in their lives, focusing on careers, stress-myriad factors are affecting fertility.
This story is from the July 29, 2024 edition of Business Standard.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the July 29, 2024 edition of Business Standard.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
Zomato stock crashes 14% in 2 days after Q3 results
Investors heavily dumped Zomato shares on Tuesday, disappointed with a surprisingly weak performance in the December quarter (Q3FY25).
Ideal for low-risk investors with goals 1-3 yrs away
Union Mutual Fund recently launched the Union Short Duration Fund, an open-ended short-duration debt scheme.
SECOND CLASS CRICKET
India stars are turning up for Ranji matches. However, with all eyes riveted on the IPL, the first-class championship is in dire need of a booster shot
e2W Makers Call For GST Rate Cuts, Relook At PM E-DRIVE Plan
With the Union Budget 2025 on the horizon, electric two-wheeler (e2W) players are urging the government to introduce critical policy measures and incentives to revitalise the sector.
More US energy exports to India likely: Puri
Trump's energy push may lead to increased American crude oil, LNG shipments to the country
Valuation Woes Negate Q3 Positives for Dixon
Shares slump 14%, prompting analysts to maintain cautious stance
Banks to overhaul terms of engagement with BCs
A First in 12 Years
NRAI calls for ONDC boost to challenge Zomato and Swiggy
The National Restaurant Association of India (NRAI), the country's leading restaurateurs' body, has decided to step up pressure on the government-backed Open Network for Digital Commerce (ONDC) to take on Zomato and Swiggy's standalone apps for 10-minute food delivery, Bistro and Snacc.
Challenges Posed by AI Dominate Talks at Davos
Union Ministers, CMs Unveil India Pavilion, Meet Leaders of Global Companies
Equities tumble, volatility surges
A slew of executive orders and announcements on Day 1 turn policymakers, investors cautious